Research suggests that Infliximab can suppress H. pylori–induced upregulation of CXCR4 by inhibiting TNF-α signaling, thereby reducing GC cell migration and exhibiting anti-tumor potential (434). This evidence concerns the gene CXCR4 and neoplasm.